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Abstract
Background: Ulinastatin or urinary trypsin inhibitor (UTI) has been shown to ameliorate the inflammatory response
induced by experimental severe acute pancreatitis (SAP) and hence reduce the mortality, however the mechanism
of its action remains incompletely understood. We have investigated the effect of ulinastatin on regulatory T-cells
(Tregs) in an established rat model of SAP.
Methods: We established a rat SAP model by injecting 5% Na-taurocholate into the pancreatic duct and treated
the SAP rats with ulinastatin with different dose level (5000, 10000, 30000 U/kg) through intraperitoneal injection at
0, 6 and 12 h.
Results: We showed that the tissue damage of pancreas and the mortality of the SAP rats were significantly
reduced by ulinastatin. We also showed that in the SAP rats the frequencies of CD4+ T cells and Tregs, as well as
the expressions of TGF-β1, CTLA-4, and Foxp3 were decreased in the SAP animals while IL-1β, IL-10 and TNF-α were
significantly increased. Treatment with ulinastatin up-regulated the proportion of Tregs in CD4+ T cells and the
expression of IL-10, Foxp3 and CTLA-4 in the SAP rats in a dose dependence fashion, while down-regulating the
levels of L-1β and TNF-α, myeloperoxidase (MPO) activity.
Conclusions: Our findings suggest that ulinastatin alleviates inflammatory response and tissue damage in SAP rats
by increasing the proportion of Tregs. Our study provides a new mechanism for the beneficial effect of ulinastatin
in SAP rat model.
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Background
Acute pancreatitis (AP) is a common abdominal disorder
characterized by systemic inflammation as well as single-
organ or multi-organ failure associated with high mortality
[1, 2]. The pro-inflammatory cytokines such as IL-1β, IL-
10, TNFα have been shown to play an important role in the
pathogenesis of AP causing tissue damage and organ
dysfunction. In the course of AP, multi-organ damage
caused in the early stage associated with systemic inflam-
matory response, followed by pancreatic necrosis in the late
stage are the two most important events responsible for the
mortality [3]. The intervention in the early stage by
targeting inflammatory response may be an effective treat-
ment strategy in the treatment of AP [4].
Urinary trypsin inhibitor (ulinastatin, UTI), a protease
inhibitor that can be obtained from the urine of healthy
people [5], was reported to have strong inhibitory activ-
ity on the pancreatic enzymes and anti-inflammatory
effect on AP [6]. Maciejewski et al. [7] showed that
ulinastatin administration increased the survival rate in
experimental animals of AP. Furthermore, previous
studies [6, 8] have shown that ulinastatin can inhibit the
expression of tumor necrosis factor-α (TNF-α), and
interleukin-1β (IL-1β), and increase the levels of IL-2
and IL-10. The studies on the mechanism of the anti-
inflammatory effect of ulinastatin have mainly been
focused on the roles of these cytokines.* Correspondence: heguanghuang2@163.com1General Surgery Department, Fujian Medical University Union Hospital,
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Regulatory T cells (Tregs), a critical immune cell lineage,
develops and matures in the thymus to regulate immune
response and maintain the immune homeostasis. Conven-
tionally, Tregs have been characterized by high expression
of CD25 in CD4+ T cells [9]. Similarly, they express cyto-
toxic T-lymphocyte antigen 4 (CTLA-4) at a high level
[10]. The fork-head/winged helix transcription factor
p3(Foxp3) is a key nuclear transcription factor to the
development and function of CD4+ Tregs [11, 12]. In
addition to regulating immune system, there is growing
evidence that Treg cells play crucial roles in controlling
progressive inflammation of many diseases [13–15].
Recently, Zheng et al. [16] demonstrated that increas-
ing the percentage of CD4+CD25+ Tregs in peripheral
blood can reduce the pancreatic inflammation and mor-
tality in a mouse model of severe AP (SAP). Another
study indicated that ulinastatin can enhance immuno-
logical function and reduce the injury in SAP rats
through inhibiting the apoptosis of CD4+ T cells [17].
Hao et al. [18] showed that UTI can attenuate inflamma-
tory response of patients undergoing cardiopulmonary
bypass by inducing the expansion of CD4+CD25+ Tregs.
These studies suggested that CD4+CD25+ Tregs may
play important roles in preventing the inflammatory
response of AP.
In the current study, we investigated the effect and the
related mechanism of ulinastatin on CD4+CD25+ Tregs
in an established rat model of SAP. We studied the
effects of ulinastatin on the dynamic changes of CD4
+CD25+ Tregs, CTLA-4, certain nuclear transcription
factor, inflammatory response, and the pathological
structure in the SAP rats.
Methods
Animals
Male Sprague–Dawley (SD) rats, weighing 200–250 g,
were obtained from the Fujian Medical University
Laboratory Animal Center (Fuzhou, China) and housed
in rooms with 12-h light–dark cycle for at least one
week. Food and tap water were provided ad libitum. All
experimental protocols were approved by the Ethical
Committee for Animal Research of Fujian Medical
University.
Preparation of severe AP animal model
Severe AP was induced in male SD rats by retrograde
injection of 5% Na-taurocholate (1 ml/kg body weight,
Inalco S.p.A., Milano, Italy) into the pancreatic duct of
the rats in accordance with the method of George Peri-
des et al. [19]. Anesthesia was performed with intraperi-
toneal injection of 10% Chloral hydrate (3 ml/kg body
weight; Bio Basic, Markham, ON, Canada). Afterwards,
the abdominal incision was closed with sutures, and the
animals received normal saline (40 mL/kg by body
weight, sc). With experience, animal survival for 24 h
following infusion reached almost 95%. The control
groups underwent laparotomy and were subjected to
insertion of a cannula into the biliopancreatic duct, but
infused nothing.
Experimental protocols
Total of 100 rats weighing 200 to 250 g were used in the
study. Fifty rats were divided into 5 groups according to
the animal model and treatment: control group, SAP
group, SAP with ulinastatin (5000 U/kg; Techpool Bio-
chemical Pharmaceutical Corporation, Guangzhou,
China), SAP with ulinastatin (10000 U/kg), SAP with uli-
nastatin (30000 U/kg). In ulinastatin treatment groups,
SAP-induced animals were administered with 1 ml uli-
nastatin through intraperitoneal injection at 0 h, 6 h and
12 h, and control group and SAP group were injected
with 1 mL normal saline instead. The 0 indicates the
moment when abdominal incision was closed. All rats
were sacrificed at 24 h, by intraperitoneal injection of
Chloral hydrate that induces lethal anesthesia. Some per-
ipheral blood samples were collected to procure mono-
nuclear cells and perform Flow Cytometry. The other
blood samples were obtained from all previously men-
tioned rats for RNAs extraction and the assessment of
serum amylase, lipase, and serum cytokines. Longitu-
dinal dissected parts of the pancreas were removed and
frozen in liquid nitrogen to prevent degradation for tis-
sue MPO activity detection; other parts were fixed in 4%
formaldehyde solution and then embedded in paraffin
for histologic analysis. The other 50 rats, also divided
into 5 groups as above, were used to evaluate the effect
of ulinastatin on the mortality rate after SAP operation,
respectively.
Serum amylase analysis and ELISA
Blood samples were centrifuged at 3000 g for 10 min at
4 °C to separate the serum. The serum amylase and
lipase level were measured with Olympus AV2700 auto-
mated clinical biochemistry analysis equipment (Olym-
pus, Tokyo, Japan), according to the manufacturer’s
instructions. Serum levels of interleukin 1β (IL-1β),
tumor necrosis factor α (TNF-α), IL-10, and TGF-β1
were measured with a rat enzyme-linked immunosorb-
ent assay (ELISA) kit (CUSABIO, Wuhan, China) in
accordance with the manufacturer’s instructions.
Pancreatic MPO assay and histological analysis
The pancreatic MPO assay was performed on frozen tis-
sue using colorimetry assay kits (Jiancheng Bioengineering
Institute, Nanjing, China), according to the manufacturer’s
instructions. Four-micrometer sections were stained with
hematoxylin and eosin (H&E) to observe the morpho-
logical changes under the light microscope. The degree of
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development of pancreatic lesions was evaluated
according to point Spormann scale, as previously
described [20]. Histological analysis was conducted in
control group, SAP group, and SAP treated with ulinas-
tatin group (30000U/kg).
Cell isolation from the peripheral blood
The mononuclear cells were isolated from the peripheral
blood by Ficoll-Hypaque gradient centrifugation (Solar-
bio Biotech, Beijing, China), washed twice with PBS, and
kept on ice until labeling.
Flow cytometry analysis
The expression markers on T cells from the peripheral
blood were determined by flow cytometry after staining
with anti-rat specific Abs conjugated with PE, FITC, or
APC. The rat Abs including anti-CD4, anti-CD25, and
anti-FoxP3 that were purchased from eBioscience (San
Diego, CA, USA). To determine the proportion of CD4+
T cells in lymphocytes and CD25 expression on the sur-
face of CD4+ T cells, the cells were stained with CD25-
PE mAb and CD4-FITC mAb for 30 min in darkness.
Concomitantly, for the detection of intranuclear Foxp3,
the cells were reacted with 1 mL of freshly prepared fix-
ation/permeabilization working solution for 2 h at 4 °C.
After washing the cells with the permeabilization buffer
twice, the cells were stained with anti-rat Foxp3-APC
antibody for 30 min in the dark. After washing, the cells
were performed on a BD Accuri C6 flow cytometer (BD
Biosciences) using the FlowJo Software (Ashland, Ken-
tucky, USA).
Real-time polymerase chain reaction
Total RNAs were extracted from peripheral blood with
TRIzol reagent (Takara, Dalian, China) followed by reverse
transcription into complementary DNA (cDNA) accord-
ing to the manufacturer’s instructions (Thermo Scientific,
Waltham, MA, USA). Real-time quantitative polymerase
chain reaction (PCR) was performed with QuantiTect
SYBR Green PCR Kit (Applied Biosystems, Foster City,
CA, USA) in ABI PRISM 7500 PCR instrument (Applied
Biosystems) according to the manufacturer’s instructions.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as an internal reference. The primers were as fol-





G-3′. The relative gene expression level was calculated by
the 2-ΔΔCt method.
Statistical analysis
Quantitative data were expressed as the mean ± standard
deviation (SD) and analyzed with a one-way ANOVA.
Fisher least significant difference was used to evaluate
significant differences between the groups. The survival
rate was calculated as percentage of survivors at the
described certain time point relative to the total number
of rats that received a given treatment. The survival rate
data were analyzed using the log-rank test. P values less
than 0.05 were considered statistically significant. All
statistical analyses were performed using SPSS statistical
software version 19.
Results
Ulinastatin significantly improves survival in SAP rat
model
All rats in the sham group survived, whereas the rats
that received SAP operation all died within 72 h (P <
0.01, Fig. 1). Intraperitoneal injection of ulinastatin
(5000 U/kg) after SAP operation reduced the mortality
rate (P > 0.05, Fig. 1). Furthermore, treatment with uli-
nastatin at higher dose (10000 and 30000 U/kg) signifi-
cantly protected the rats from SAP (P < 0.05, Fig. 1).
Effect of ulinastatin on SAP-induced enzyme production
and MPO
We assessed the severity of AP by measuring amylase
and lipase levels, the known biomarkers of SAP. Neu-
trophils are known to contribute to the activation of
trypsinogen to cause further damage in SAP. There-
fore we next examined neutrophil infiltration by
measuring MPO in pancreas homogenates. The serum
amylase and lipase levels were increased significantly
in the SAP group compared to the control group,
indicating that SAP rat model was induced success-
fully (P < 0.01, Fig. 2a and b). Treatment with
Fig. 1 Ulinastatin treatment improves survival in SAP rats. Ulinastatin
was administered immediately when SAP operation achieved and
administered again in 6 h later and again in 12 h later through
intraperitoneal injection. Data are shown as percent of rats surviving
(n = 10). *P < 0.05 when compared with the SAP group
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ulinastatin significantly reduced the levels of amylase
and lipase in the SAP-induced rats (P < 0.01) com-
pared to the untreated animals. In addition, this effect
was dose dependent as ulinastatin at 30000U/kg
showed pronounced effect than the 5000U/kg dose
(Fig. 2a and b). Furthermore, a similar result was ob-
tained in pancreatic MPO activities (Fig. 2c).
Ulinastatin reduced SAP-induced tissue damage of pancreas
Histologically, the pancreatic sections from the control
group showed normal architecture (Fig. 3a). In contrast,
the pancreatic sections from the SAP animals showed
apparent destruction of normal architecture, tissue
edema, necrosis of acinar cells, and infiltration of inflam-
matory cells, with the median point Spormann scale of
Fig. 2 Effects of ulinastatin on SAP-induced enzyme production and MPO. a Serum levels of amylase. b Serum levels of lipase. c MPO activity.
Data were expressed as means ± SD. n = 10 for each group. **P < 0.05 when compared with the control group; *P < 0.05 when compared with the
SAP group; #P < 0.05 when compared with the SAP + Ulinastatin (5000U/kg) group; ##P < 0.05 when compared with the SAP + Ulinastatin
(10000U/kg) group
Fig. 3 Histopathology of pancreas. a The pancreatic parenchyma showed typical normal architecture in control group, white arrow indicate
normal acinar cell. b The pancreatic section showed significant destruction of structure in SAP group. c After ulinastatin (3000U/kg) treatment, the
pancreatic damage was less severe than that in the SAP group. Single black arrows indicate glands damage and acinar cells necrosis, double
black arrows indicate tissue oedema, treble black arrows indicate inflammatory cells infiltration. d Pancreas histopathologic score were evaluated
according to point Spormann scale, and the results were expressed as means ± SE. n = 10 for each group. **P < 0.05 when compared with the
control group; *P < 0.05 when compared with the SAP group. Magnification, ×200
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16 (P < 0.01, Fig. 3b and d). After treatment with ulinas-
tatin (3000U/kg), the tissue damage was significantly
reduced with the median point Spormann scale of 11 (P
< 0.05, Fig. 3c and d).
Effect of ulinastatin on cytokines production
The injury of acinar cells in acute pancreatitis is
followed by a pro-inflammatory cascade leading to pan-
creatic necrosis and systemic inflammatory response
syndrome both in human and in experimental animal
models. TNF-α and IL-1β are pro-inflammatory cyto-
kines that are known for their ability to induce systemic
inflammation. In contrast to the control group, the
expression of both cytokines in SAP was significantly
elevated compared to the normal animals (Fig. 4a and
b). Treatment with ulinastatin reduced the level of TNF-
α and IL-1β in a dose-dependent way (P < 0.05). TGF-β1
and IL-10 are Treg-related cytokines characterized as
immunosuppressive or anti-inflammatory mediators. IL-
10 level was increased in the SAP animals compared to
the controls while TGF-β1 showed decrease instead (P <
0.05). Ulinastatin treatment (10000 and 30000 U/kg) of
SAP rats led to a significant increase in the serum
concentration of IL-10, but no change in serum TGF-β1
level (Fig. 4c and d).
Ulinastatin does not alter the proportion of CD4+ T
lymphocytes in the SAP rats
We explored the effect of ulinastatin on the peripheral
blood CD4+ T cells in SAP rats by flow cytometry
(Fig. 5). The SAP animals showed a lower percentage of
CD4+ T lymphocytes compared to the controls (P <
0.05). There was no significant difference in the propor-
tion of CD4+ T lymphocytes between SAP animals and
SAP animals treated with ulinastatin.
Ulinastatin enhances the percentage of Treg in CD4+ T
cells in the SAP rats
We next studied the change in Tregs of the SAP animals
treated with ulinastatin. The proportion of CD4+CD25+ T
cells was decreased significantly in the SAP group, com-
pared to the control group (P < 0.05, Fig. 6a and b). In
contrast, ulinastatin (10000 and 30000 U/kg) effectively
prevented the decline of CD4+CD25+ T cells (P < 0.05,
Fig. 6a and b). Tregs were also defined as CD4+CD25
+FoxP3+ T cells. We studied the effect of ulinastatin on
Fig. 4 Effects of ulinastatin on serum cytokines in the SAP rats. a Serum levels of IL-1β. b Serum levels of TNF-α. c Serum levels of IL-10. d Serum
levels of TGF-β1. Data were expressed as means ± SD. n = 10 for each group. **P < 0.05 when compared with the control group; *P < 0.05 when
compared with the SAP group; #P < 0.05 when compared with the SAP + Ulinastatin (5000U/kg) group; ##P < 0.05 when compared with the SAP +
Ulinastatin (10000U/kg) group
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Fig. 5 The effect of ulinastatin on circulating CD4+ T cells in SAP rats. R1 region represents CD4+ T cell in lymphocytes. The frequencies (%) of
CD4+ T Cells were measured by using flow cytometry. Results were shown as means ± SD. n = 10 for each group. **P < 0.05 when compared with
the control group
Fig. 6 The effect of ulinastatin on Treg cells in SAP rats. a R2 region represents CD4+CD25+ T cells from lymphocytes. b The frequencies (%) of
CD4+CD25+ T cells. c R3 region represents CD4+CD25+FoxP3+ T cells from CD4+ T cells. d The frequencies (%) of CD4+CD25+FoxP3+ T cells.
Results were measured by using flow cytometry and shown as means ± SD. n = 10 for each group. **P < 0.05 when compared with the control
group; *P < 0.05 when compared with the SAP group; #P < 0.05 when compared with the SAP + Ulinastatin (5000U/kg) group; ##P < 0.05 when
compared with the SAP + Ulinastatin (10000U/kg) group
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the proportion of CD4+CD25+FoxP3+ T cells in CD4+ T
cells, and obtained similar results (Fig. 6c and d).
Effect of ulinastatin on Foxp3 and CTLA-4 gene
expression
To explore the potential influence of ulinastatin on im-
munoregulatory molecules in Tregs, the expression of
Foxp3 and CTLA-4 was determined with RT-PCR using
lymphocytes isolated from the peripheral blood. Com-
pared to the control group, the messenger RNA (mRNA)
levels of Foxp3 and CTLA-4 in SAP group were signifi-
cantly decreased (P < 0.05, Fig. 7). Moreover, treatment
with ulinastatin further up-regulated the expression of
Foxp3 and CTLA-4 in SAP rats in a dose dependence
fashion, and at the 30000U/kg dose level the effect was
the most pronounced (P < 0.05).
Discussion
The techniques of inducing animal model of SAP
include pancreatic under-capsule injection or biliopan-
creatic duct retrograde injection of sodium taurocholate,
intraperitoneal injection of caerulein alone or injection
of caerulein combined with lipopolysaccharide, ethionine
diet and hypercalcemia derivation [21, 22]. The tech-
nique of Aho et al. [23] by retrogradely injecting sodium
taurocholate into biliopancreatic duct through duodenal
papilla puncture could more reliably induce the SAP
animal model. It could reflect the patho-physiologic
mechanism of acute biliary pancreatitis, a common cat-
egory of clinical SAP. However, the technique causes a
high damage rate of biliopancreatic duct and results in
bile leakage. To overcome this problem, George Perides
et al. [19] changed the way of injection by creating a
small hole in the duodenal wall opposite to the papilla,
followed by puncturing a cannula to complete the injec-
tion. In our study, a stable and reliable animal model
was induced successfully by the modified technique of
George Perides. Levels of serum amylase and lipase in
SAP group were consistently elevated over the control
group. Furthermore, the pathologic changes such as large
necrosis area, edema and infiltration of inflammatory cells
were observed in pancreatic tissue of the SAP rats.
Inflammatory cytokines including IL-1, IL-2, IL-4, IL-
10 and TNF-α, are released early in the course of SAP
leading to the systemic inflammatory response which
represents the core problem of SAP. In the recent years,
evidence has accumulated that immune reactions and
immune cells like CD4+ T cells and Tregs play important
roles in the AP pathogenesis [24, 25]. Hence, inhibiting
pro-inflammatory mediators [26, 27] and regulating im-
mune reactions [25] are important considerations in the
therapy of SAP. It has been confirmed that ulinastatin
prevents the inflammatory response induced by SAP
[28], and evidence also indicates that ulinastatin can
regulate the immunological function through these spe-
cial immune cells [18, 29]. In the present study, we dem-
onstrated that in SAP rat model, pro-inflammatory
cytokines TNF-α and IL-1β and anti-inflammatory cyto-
kine IL-10 all were increased significantly, while TGF-β
was decreased. Treatment of ulinastatin led to decreased
levels of TNF-α, IL-1β, and increased level of IL-10, thus
attenuated the acute inflammatory response and im-
proved the survival rate in the SAP rats. We also found
that CD4+ T cells and Tregs were significantly decreased.
The mRNA levels of CTLA-4 and Foxp3 were decreased
in the SAP animals. These results indicate that not only
inflammatory response, but also immune dysfunction
play important roles in SAP, resulting in high mortality
rate of SAP.
Tregs are pivotal to the maintenance of immune
system, and key to a measured inflammatory response.
Treg-related cytokines, IL-10 and TGF-β are important
Fig. 7 The effect of ulinastatin on mRNA expression of CTLA-4 and Foxp3 in SAP rats. a mRNA expression of CTLA-4. b mRNA expression of
Foxp3. Results were expressed as means ± SD. n = 10 for each group. **P < 0.05 when compared with the control group; *P < 0.05 when compared
with the SAP group; #P < 0.05 when compared with the SAP + Ulinastatin (5000U/kg) group; ##P < 0.05 when compared with the SAP + Ulinastatin
(10000U/kg) group
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regulators of inflammation. During the inflammatory
process, IL-10 plays the role of an anti-inflammatory
cytokine, and its anti-inflammatory effect in turn
regulates the function of Tregs. Some studies have
demonstrated that IL-1 can affect the function of Tregs
[30, 31]. Tregs express IL-1 receptor (IL-1R) and can
activate p38/JNK signaling in response to IL-1 [32]. Like
IL-1, TNF-α is a pleiotropic cytokine promoting inflam-
matory mediator cascade reaction and also impairing
Treg stability and function. For instance, several studies
have revealed that Tregs were functionally abnormal in
patients with rheumatoid arthritis (RA), and TNF-α was
the key mediator of this abnormal immune regulation
[33, 34]. We found in our study that, in SAP-induced
rats treated with ulinastatin, the percentage of Tregs
increased significantly, in addition the expression of
CTLA-4 and Foxp3 were increased, in a dose-
dependence manner. Ulinastatin did not affect TGF-β1
level or the proportion of CD4+ T cells. Treatment with
ulinastatin lessened the pancreatic tissue injury and the
MPO activity, likely by enhancing the anti-inflammatory
function of Tregs with the increased proportion of CD4+
T cells. The mechanism of ulinastatin inducing the
expansion of Tregs may be through up-regulating IL-10
level and down-regulating TNF-α and IL-1β.
However, at present, it is still not clear whether the
changes of these inflammatory cytokines are the primary
mechanism of ulinastatin or indirect consequence of the
reduced inflammatory injury after treatment with ulinas-
tatin. In addition, the mechanism is not yet clear if
ulinastatin up-regulates Tregs directly or indirectly. Also
some studies showed that TNF-α can enhance the
suppressive activity of Tregs [35]. The interplay between
Tregs and inflammatory cytokines is complex and intim-
ately connected and remains to be further studied.
Conclusions
In conclusion, our study showed ulinastatin alleviates
the pancreatic injury through reducing the level of
MPO, pro-inflammatory cytokines, serum amylase and
lipase. Our study also showed that ulinastatin up-
regulated the percentage of Tregs and their anti-
inflammatory function through regulating inflammatory
cytokines and increasing the level of Foxp3 and CTLA-4
expression, providing evidence for a new mechanism re-
sponsible for the effect of ulinastatin in SAP.
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